Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Published on 27 Feb 2024 on Zacks via Yahoo Finance

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics FATE reported fourth-quarter 2023 loss of 45 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents and the year-ago loss of 58 cents.

The loss narrowed year over year due to lower research and development (R&D) expenses.

The company earned collaboration revenues of $2 million, which also surpassed the Zacks Consensus Estimate of $1 million but was down from $44 million reported in the year-ago quarter.

Read the rest of the article

NASDAQ.FATE price evolution

NASDAQ.PBYI price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Shares of Viatris, Inc. VTRS lost 4.8% in the last three trading sessions after the company repor...

Zacks via Yahoo Finance 5 Mar 2024

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript February 29, 2024 Puma Bi...

Insider Monkey via Yahoo Finance 2 Mar 2024

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value Estimate

Key Insights Puma Biotechnology's estimated fair value is US$11.07 based on 2 Stage Free Cash Flo...

Simply Wall St. via Yahoo Finance 2 Mar 2024

Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 1 Mar 2024

Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023

Net Income: PBYI reported a net income of $12.3 million in Q4 2023, a significant improvement fro...

GuruFocus.com via Yahoo Finance 1 Mar 2024

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

Puma Biotechnology, Inc. PBYI reported fourth-quarter 2023 adjusted earnings of 31 cents per shar...

Zacks via Yahoo Finance 1 Mar 2024

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

Novavax, Inc. NVAX reported a fourth-quarter 2023 loss of $1.44 cents per share, much wider than ...

Zacks via Yahoo Finance 29 Feb 2024

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance Biopharma, Inc. TBPH reported fourth-quarter 2023 adjusted net income of 3 cents per s...

Zacks via Yahoo Finance 27 Feb 2024

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

We expect investors to focus on Puma Biotechnology, Inc.’s PBYI progress with its sole marketed d...

Zacks via Yahoo Finance 27 Feb 2024

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics FATE reported fourth-quarter 2023 loss of 45 cents per share, narrower than the...

Zacks via Yahoo Finance 27 Feb 2024

News

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

NASDAQ.FATE price evolution

NASDAQ.PBYI price evolution

Want to become a better investor?